Structure Therapeutics Inc. (GPCR) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$35.00

From 52W high−62.68%

Volume1.51M

Market cap$2.50B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$35.00

From 52W high

−62.68%

Volume

1.51M

Market cap

$2.50B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.5x

P/E (TTM)

—

RSI (14)

21.8

MomentumView details →

1D Return

−0.28%

YTD Return

−50.38%

SummaryUpdated Jun 1, 2026

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in South San Francisco, California. The company was formerly known as ShouTi Inc. before rebranding and went public in February 2023. Structure Therapeutics focuses on developing novel oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) to treat chronic diseases with significant unmet medical needs, particularly in diabetes, obesity, and pulmonary diseases.

Ask drillr about Structure Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−15.88%

ROA (TTM)

−15.09%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+2.88%

FCF YoY

−36.70%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−2.56%

EBITDA YoY

−6.19%

MomentumView details →

1D Return

−0.28%

YTD Return

−50.38%

1Y Return

+46.35%

RSI (14)

21.8

vs 50D SMA

−27.95%

vs 200D SMA

−36.69%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

20.75x

Quick Ratio

20.75x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.49

EPS Surprise

−25.64%

Beats (12Q)

6/12

Next Q EPS Est

−$0.33

Avg Surprise (4Q)

−7.67%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−215.06M

Op. CF (TTM)

−220.25M

Next earningsNov 5, 2026 →

Latest newsMore news →

Structure Therapeutics is advancing its oral GLP-1 candidate aleniglipron into Phase 3 studies, with pivotal data expected in Q4 2028.30d ago

Similar companies

Viridian Therapeutics, Inc.VRDN Mineralys Therapeutics, Inc.MLYS Vera Therapeutics, Inc.VERA Harmony Biosciences Holdings, Inc.HRMY Pharvaris N.V.PHVS Beam Therapeutics Inc.BEAM Find similar companies →

Latest newsMore news →

Structure Therapeutics reported positive clinical data for its oral small molecule amylin receptor agonist ACCG-2671 and GLP-1 receptor agonist aleniglipron for chronic weight management, including Phase 1/2a results for ACCG-2671 and Phase 2 OLE results for aleniglipron showing up to 16.2% mean body weight reduction at 72 weeks.12d ago Structure Therapeutics is advancing its oral GLP-1 candidate aleniglipron into Phase 3 studies, with pivotal data expected in Q4 2028.30d ago Structure Therapeutics Inc. reported a net loss of $106.2 million for Q2 2026, with research and development expenses of $100.1 million and general and administrative expenses of $18.6 million.45d ago